HHS Announces Interim Enforcement Discretion for Select Compounded Peptides: What Healthcare Practices and Med Spas Need to Know

Oct 28, 2026 | Legal Compliance, News

Federal policy on compounded peptides just reached a pivotal milestone. On October 28, 2026, the Department of Health and Human Services (HHS) released an interim enforcement discretion policy governing the use of select peptide bulk drug substances in 503A...

FDA Authorizes Lynch Regenerative Medicine’s IND for Phase IIb Trial of Injectable rhPDGF-BB in Infraorbital Hollowing: What Aesthetic Practices Need to Know

Oct 21, 2026 | News, Risk Management

On October 21, 2026, Franklin, Tennessee-based Lynch Regenerative Medicine, LLC (LRM) announced that the U.S. Food and Drug Administration (FDA) has authorized its Investigational New Drug (IND) application to proceed with a Phase 2 clinical trial evaluating...

FDA Moves Toward Expanded Peptide Compounding Access: What Med Spas and Wellness Clinics Need to Know

Oct 16, 2026 | Legal Compliance, News

The FDA may be preparing to ease restrictions on certain compounded peptides, potentially opening the door for medical spas, wellness clinics, and healthcare providers to offer treatments that have faced significant federal regulatory scrutiny in recent years. On...

ASPS Releases 2025 Plastic Surgery Statistics: The “GLP-1 Effect” and Shift Toward Restoration

Sep 4, 2026 | News

The American Society of Plastic Surgeons (ASPS) has officially released its 2025 Procedural Statistics Report, offering an in-depth analysis of surgical and non-surgical aesthetic trends nationwide. The data reveals an overall 7% increase in cosmetic surgical...

FDA Warns R3 Medical Companies Over Unapproved Regenerative Products

Sep 2, 2026 | Legal Compliance, News, Risk Management

The U.S. Food and Drug Administration (FDA) has issued a detailed Warning Letter (CBER 26-726330) to Scottsdale, Arizona-based R3 Medical Companies, its affiliated entities Bello Bio, LLC and Regen Suppliers, LLC, and CEO David L. Greene, M.D. Following joint facility...

Mississippi’s Medical Boards Draw a Hard Line on Research-Grade Peptides: What Med Spas and Wellness Clinics Need to Know

Sep 1, 2026 | Legal Compliance, News, State-Specific Regulations

Mississippi’s three healthcare licensing boards have put the state’s providers on notice: there is no safe harbor for offering “research-grade” peptides to patients. In a joint statement issued by the Mississippi State Board of Medical...